vTv Therapeutics Randomizes First Participant in Phase 2a Study
vTv Therapeutics randomized the first participant in its Phase 2a cadisegliatin study for type 1 diabetes.
vTv Therapeutics randomized the first participant in its Phase 2a cadisegliatin study for type 1 diabetes.